

Ashish Sharma

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6487346/ashish-sharma-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

300
citations

10
h-index

14
g-index

58
ext. papers

512
ext. citations

4.1
avg. IF

4.13
L-index

#	Paper	IF	Citations
40	Ranizurel safety evaluation in real-world -(RaSER) study.. <i>American Journal of Ophthalmology Case Reports</i> , 2022 , 25, 101358	1.3	0
39	The Port Delivery System with ranibizumab-journey of mitigating vitreous hemorrhage. <i>Eye</i> , 2021 ,	4.4	2
38	Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). <i>Eye</i> , 2021 ,	4.4	2
37	Re: Kunimoto et al.: Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study (Ophthalmology. 2020;127:1331-1334). <i>Ophthalmology</i> , 2021 , 128, e30	7.3	
36	Brolucizumab-early real-world experience: BREW study. <i>Eye</i> , 2021 , 35, 1045-1047	4.4	18
35	Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. <i>Eye</i> , 2021 , 35, 1292-1294	4.4	11
34	Biosimilars for Retinal Diseases: An Update. <i>American Journal of Ophthalmology</i> , 2021 , 224, 36-42	4.9	13
33	Brolucizumab-foreseeable workflow in the current scenario. <i>Eye</i> , 2021 , 35, 1548-1550	4.4	6
32	Fluid based visual prognostication in Type 3 macular neovascularization (MNV)- FLIP-3 Study. <i>Retina</i> , 2021 , 42,	3.6	1
31	Vortex vein anastomosis and pachychoroid-an evolving understanding. <i>Eye</i> , 2021 , 35, 1545-1547	4.4	3
30	Brolucizumab-key learnings from HAWK and HARRIER. <i>Eye</i> , 2020 , 34, 1318-1320	4.4	2
29	Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study. <i>International Ophthalmology</i> , 2020 , 40, 3067-3075	2.2	1
28	MII RetCam assisted smartphone-based fundus imaging (MSFI)-A boon for paediatric retinal imaging. <i>Eye</i> , 2020 , 34, 1307-1309	4.4	0
27	Smartphone based ROP (S-ROP) screening-opportunities and challenges. <i>Eye</i> , 2020 , 34, 1512-1514	4.4	1
26	Brolucizumab and immunogenicity. <i>Eye</i> , 2020 , 34, 1726-1728	4.4	15
25	Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum. <i>Eye</i> , 2020 , 34, 1501-1503	4.4	4
24	Brolucizumab-another anti-VEGF or beyond. <i>Eye</i> , 2020 , 34, 1499-1500	4.4	4

23	MIIRetCam (Make In India Retina Camera) assisted retinal imaging in paediatric patients: Useful, artefacts, learning curve. <i>Journal Francais D'Ophthalmologie</i> , 2020 , 43, e35-e38	0.8	2
22	Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. <i>Eye</i> , 2020 , 34, 1008-1009	4.4	9
21	Faricimab: expanding horizon beyond VEGF. <i>Eye</i> , 2020 , 34, 802-804	4.4	24
20	Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. <i>Eye</i> , 2020 , 34, 1006-1007	4.4	8
19	Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression. <i>Eye</i> , 2020 , 34, 422-423	4.4	4
18	Brolucizumab: is extended VEGF suppression on the horizon?. <i>Eye</i> , 2020 , 34, 424-426	4.4	5
17	Brolucizimab-leading an era of structural revolution for long-term VEGF suppression. <i>Eye</i> , 2020 , 34, 611-613	4.4	10
16	Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study. <i>Eye</i> , 2020 , 34, 1063-1068	4.4	10
15	Abicipar pegol: the non-monoclonal antibody anti-VEGF. <i>Eye</i> , 2020 , 34, 797-801	4.4	8
14	Ophthalmic biosimilars and biologics-role of endotoxins. <i>Eye</i> , 2020 , 34, 614-615	4.4	5
13	Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. <i>British Journal of Ophthalmology</i> , 2020 , 104, 2-7	5.5	17
12	Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study. <i>International Ophthalmology</i> , 2020 , 40, 67-72	2.2	4
11	Biologics, biosilimars, and biobetters: different terms or different drugs?. <i>Eye</i> , 2019 , 33, 1032-1034	4.4	4
10	Biotherapeutics and immunogenicity: ophthalmic perspective. <i>Eye</i> , 2019 , 33, 1359-1361	4.4	13
9	Role of retinal image-based counseling in the treatment of peripheral retinal lesions. <i>Eye</i> , 2019 , 33, 161-163	4.4	1
8	Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management: A Potential Cost-Effective Treatment Strategy to Be Explored. <i>Ophthalmology Retina</i> , 2019 , 3, 1009-1011	3.8	0
7	Comparison of a Smartphone-Based Photography Method with Indirect Ophthalmoscopic Assessment in Referable Retinopathy of Prematurity: A Smart Retinopathy of Prematurity Model Pilot Study. <i>Ophthalmology Retina</i> , 2019 , 3, 911-912	3.8	10
6	Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019 ;126:1141-1154). <i>Ophthalmology</i> , 2019 , 126, e87-e88	7.3	4

5	Re: Dugel et al: HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brodalumab for neovascular age-related macular degeneration (Ophthalmology. 2019 Apr 12 [Epub ahead of print]). <i>Ophthalmology</i> , 2019 , 126, e95-e96	7.3	2
4	Biosimilars in ophthalmology: "Is there a big change on the horizon?". <i>Clinical Ophthalmology</i> , 2018 , 12, 2137-2143	2.5	47
3	Effects of light on retinal pigment epithelial cells, neurosensory retinal cells and Müller cells treated with Brilliant Blue G. <i>Clinical and Experimental Ophthalmology</i> , 2015 , 43, 820-9	2.4	10
2	Effects of dexamethasone on human trabecular meshwork cells in vitro. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2013 , 251, 1741-6	3.8	5
1	Fear of safety compromise with biosimilar anti-VEGF perception or truth. <i>Eye</i> ,	4.4	0